Acquisition synergy 360biolabs was acquired by BioAgilytix, a leader in large molecule drug development support. Leveraging the combined expertise, the company can now offer a more comprehensive range of services, presenting an opportunity for cross-selling to existing and new clients.

Strategic partnerships By partnering with Cosec, Nucleus Network, and others for clinical trials in Australia, 360biolabs has expanded its network and visibility in the region. This opens up avenues for collaboration and potential referrals within the industry ecosystem.

Cutting-edge technology 360biolabs utilizes advanced technology like Statcounter, Cloudflare, and MySQL in its laboratory operations. Highlighting these tech tools in sales pitches can demonstrate the company's commitment to innovation and quality, appealing to tech-savvy clients seeking state-of-the-art solutions.

Service diversification With expertise in a wide array of assays and specialized services such as PK, PD, LC/MS, and Virology, 360biolabs can tailor offerings to diverse client needs. This versatility presents an opportunity to cater to a broad range of client requirements and potentially upsell additional services.

Global presence advantage 360biolabs has laboratories in the US and Europe, enhancing its global reach and credibility. This multinational presence can be leveraged in sales discussions to emphasize the company's international experience and capability to attract multinational clients looking for a partner with a broad geographical footprint.